Attached files

file filename
10-Q - FORM 10-Q - ARIAD PHARMACEUTICALS INCd333019d10q.htm
EX-31.2 - SECTION 302 CFO CERTIFICATION - ARIAD PHARMACEUTICALS INCd333019dex312.htm
EX-10.1 - AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT - ARIAD PHARMACEUTICALS INCd333019dex101.htm
EX-10.5 - FORM OF 2012 PERFORMANCE SHARE CERTIFICATE - ARIAD PHARMACEUTICALS INCd333019dex105.htm
EX-10.4 - DIRECTOR COMPENSATION ARRANGEMENTS - ARIAD PHARMACEUTICALS INCd333019dex104.htm
EX-10.2 - FIRST AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT - ARIAD PHARMACEUTICALS INCd333019dex102.htm
EX-31.1 - SECTION 302 CEO CERTIFICATION - ARIAD PHARMACEUTICALS INCd333019dex311.htm
EXCEL - IDEA: XBRL DOCUMENT - ARIAD PHARMACEUTICALS INCFinancial_Report.xls
EX-10.3 - FIRST AMENDMENT TO AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT - ARIAD PHARMACEUTICALS INCd333019dex103.htm

Exhibit 32.1

Certification

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

The Quarterly Report on Form 10-Q for the period ended March 31, 2012 (the “Form 10-Q”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, and information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 9, 2012

 

/s/ Harvey J. Berger, M.D

  Harvey J. Berger, M.D.
  Chairman and Chief Executive Officer

Date: May 9, 2012

 

/s/ Edward M. Fitzgerald

  Edward M. Fitzgerald
  Executive Vice President,
  Chief Financial Officer

A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.